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THESIS ABSTRACT 
Background: With survivorship increasingly recognised as a distinct phase of cancer care, 
uncertainty has emerged within the oncology community regarding the roles and 
responsibilities of those caring for cancer survivors. Consequently, many cancer survivors are 
ill-informed of the potential challenges associated with the survivorship phase. Cognitive 
changes experienced by cancer survivors have received growing attention as a survivorship 
issue. Though often subtle in nature, cancer related cognitive changes (CRCC) can have a 
profound impact on a cancer survivor’s quality of life (QOL). Nonetheless, cancer survivors 
report receiving limited information by treating oncologists regarding this phenomenon. 
Aim: To explore the perceptions of oncology specialists regarding CRCC, and how their 
views may influence decisions about patient care.    
Overview of the Thesis: The thesis is divided into two sections. Section I is a review of the 
existing and relevant literature relating to CRCC and their effects on cancer survivors’ QOL, 
with a particular focus on the survivorship phase. A description of the search strategies used 
to locate literature is also included.  
Section II is a manuscript formatted for submission to the journal Psycho-Oncology. This 
manuscript outlines the findings of a qualitative study exploring oncologists’ understandings 
of CRCC, and their perceived role in the management of cancer survivors’ cognitive concerns 
across the continuum of cancer care.  
Findings from the project as a whole demonstrate the uncertainty of oncology specialists 
regarding the appropriate management of CRCC, and the need for specific interventions and 
clinical practice guidelines to address the effects of CRCC on cancer survivors’ daily 
functioning and QOL.  
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Literature Search Strategy 
A search of the literature was conducted using the electronic databases CINAHL, 
Medline and Web of Science. For each database, the search terms used were “cancer” OR 
“neoplasms” AND “cognition” OR “memory” OR “function” AND “oncologist” AND 
“perception” OR “belief” OR “opinion” AND “qualitative”. “Qualitative” was included in the 
search in order to identify gaps in this particular area of research, and thus inform the study’s 
design. Results were limited to English language publications from 1994 to present. To 
ensure a thorough review was performed, the reference lists of each article relating to the 
topic were screened to identify further studies not located in the initial database search.  
The International Cancer and Cognition Taskforce (ICCT) website also contains a list 
of articles relating to cancer and cognitive changes. The library was searched for research not 
previously identified in this search strategy.  
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Introduction 
The purpose of this literature review is to inform and provide direction for the 
subsequent study The Perceptions of Australian Oncologists Regarding Cognitive Changes.  
Four key areas of research are reviewed including cancer survivorship, patient-centred cancer 
care, cancer-related cognitive changes (CRCC) and the management of cancer survivors’ 
cognitive concerns. The review begins with a background of cancer prevalence and survival 
in Australia. This is followed by a brief history of cancer survivorship, including the 
redefining of the term ‘cancer survivor’. Patient-centred cancer care is then discussed, with a 
particular focus on patient-clinician communication and the purpose of survivorship care 
plans. This is followed by an overview of the lasting effects of a cancer experience. The 
effects of CRCC on cancer survivors is critically examined, including potential causes and 
their long-term effects on quality of life (QOL). Cancer survivors’ experiences with raising 
cognitive concerns to oncology specialists are explored. Finally, the evidence surrounding the 
awareness of oncology specialists regarding CRCC are critiqued, and limitations of this 
literature are identified. This review highlights the need for further research exploring the 
perceptions of oncologists regarding CRCC, and how their views may influence decisions 
about patient care. Although cancer survivors report the profound, long-term impacts of 
cognitive changes on daily functioning and QOL, reasons why the discussion around CRCC 
is more commonly initiated by cancer survivors or not addressed at all remains unclear in the 
current body of research. It is this question that the subsequent study aims to address. 
 
The Prevalence of Cancer and Survival in Australia 
The term ‘cancer’ refers to a group of diseases characterised by the uncontrollable 
multiplication of cells in the body. These abnormal cells damage tissues in the surrounding 
region and, if unsuccessfully treated, can metastasise to other regions of the body and 
potentially cause mortality (AIHW & AACR, 2012). 
The Australian Institute of Health and Welfare (AIHW) in collaboration with the 
Australasian Association of Cancer Registries (AACR) (2012) reported that one in two 
Australians will be diagnosed with cancer during their lifetime, and one in five of these 
Australians will die from the disease before the age of 85 years. The report estimated that 
over 120,000 Australians would be diagnosed with cancer in 2012 (excluding certain skin 
carcinomas), a figure that has almost doubled since 1991 (AIHW & AACR, 2012). The 
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increase in diagnoses for prostate cancer, breast cancer in females, bowel cancer and lung 
cancer is the primary reason for this rising figure (AIHW & AACR, 2012).  Approximately 
56% of males will account for all cancer diagnoses. Prostate cancer was the most commonly 
diagnosed cancer in males (18,560 cases), followed by bowel cancer (8,760), melanoma of 
the skin (7,440), lung cancer (6,620) and non-Hodgkin lymphoma (2,620). In females, breast 
cancer (14,560 cases) was the most commonly diagnosed, followed by bowel cancer (7,080), 
melanoma of the skin (5,070), lung cancer (4,650) and uterine cancer (2,270) (AIHW & 
AACR, 2012).    
While cancer prevalence in Australia has increased, so have survival rates for people 
diagnosed with cancer. Five-year survival rates overall have increased from 47% between 
1982 and 1987, to 66% between 2006 and 2010 (AIHW & AACR, 2012). According to the 
latest report on cancer prevalence in Australia, survival rates were highest for people 
diagnosed with thyroid cancer, lip cancer and melanoma of the skin (AIHW & AACR, 2012). 
Increasing survival rates can be attributed to improvements in early detection, diagnostic 
methods and treatment (Dickman & Adami, 2006).  
Despite increasing survival rates, for many, a cancer diagnosis is life changing 
(Hewitt, Greenfield and Stovall, 2005). As the prevalence of cancer and survival continues to 
rise in Australia, it raises questions about the management of any lasting effects on a cancer 
survivor’s health and well-being. 
 
Redefining ‘Cancer Survivor’ 
Historically, the term ‘cancer survivor’ described someone who lived disease-free for 
at least five years after treatment (Rowland, Hewitt & Ganz, 2006). Today, five-year survival 
rates are commonly referenced for the purpose of research and national health statistics 
(Leigh, 2007). However, missing from current national datasets are means to capture the 
experiences of those living with a cancer diagnosis, and the unique needs of these individuals 
as a result of cancer survivorship (Leigh, 2007).  
Before the mid-1970s, less than half of those diagnosed with cancer were expected to 
live past five years from the time of diagnosis (Rowland, Mariotto, Aziz & Tesauro, 2004). 
As five-year survival rates increased, a cancer survivorship advocacy community arose 
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throughout the 1970s and 1980s and attention was drawn to the long-term psychosocial, 
economic and legal ramifications of a cancer experience (Hewitt et al., 2005).  
In an attempt to unify the expanding efforts of this community, the National Coalition 
for Cancer Survivorship (NCCS) was formed in the United States in 1986; representing an 
international milestone for cancer survivorship. The NCCS advocated for the right of an 
individual to identify as a cancer survivor across the continuum of cancer care. Thus, the 
NCCS redefined cancer survivorship to incorporate the individual, their family, caregivers 
and friends “from the time of diagnosis and for the balance of life” (National Coalition for 
Cancer Survivorship, n.d., “Our history”, para. 1). For the purpose of this review, the NCCS 
working definition of cancer survivor will be used to incorporate individuals and populations 
living with a cancer diagnosis at any phase across the continuum of cancer care.  
 
The Survivorship Phase 
In 2005, the Institute of Medicine (IOM) in the United States released the report From 
Cancer Patient to Cancer Survivor: Lost in Transition. Though survivorship is not a new 
concept in cancer care, the report identified three major trends occurring within the area of 
cancer survivorship. Firstly, healthcare systems are acknowledging the chronic nature of the 
disease as more cancer survivors are living longer. Secondly, there has been an emergence of 
care models addressing the complex needs of individuals with chronic conditions. Thirdly, 
consumer advocacy for the provision of patient-centred care across the cancer trajectory 
continues to strengthen (Hewitt et al., 2005). Thus, the report aimed to raise awareness within 
the oncology community regarding the long-term implications of cancer and its treatment on 
survivors’ QOL, and identify strategies to improve the quality of survivorship care (Hewitt, et 
al., 2005).   
Previously, the focus of cancer care has reflected a curative approach in the areas of 
clinical practice and research, and as a result, less attention has been given to the survivorship 
phase (Cheung, Neville, Cameron, Cook & Earle, 2009; Hewitt et al., 2005). The report 
highlighted the importance of a distinct survivorship phase in cancer care for the ongoing 
provision of quality services, information and support post-treatment (Hewitt et al., 2005). 
The main components of the survivorship phase include: prevention and surveillance of 
cancer recurrence and the potential late effects of a cancer diagnosis and treatment, 
interventions for the physical and psychological implications of a cancer experience, and 
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collaboration between oncology specialists and general practitioners (GPs) for the 
coordination of cancer survivors’ long-term care needs (Ganz, 2006; Hewitt et al., 2005).  
As survivorship becomes increasingly recognised as a distinct phase of cancer care, 
uncertainty has emerged within the oncology community regarding the roles and 
responsibilities of those caring for cancer survivors (Cheung et al., 2009; Mao et al., 2009; 
Nissen et al., 2007). In a quantitative study, cancer survivors, GPs and oncologists were 
surveyed to compare perceived responsibilities in the provision of survivorship care (Cheung 
et al., 2009). Although the study found similarities in the expectations of cancer survivors and 
oncologists regarding the responsibility of oncologists in screening for primary cancer 
recurrence, cancer survivors had higher expectations than oncologists regarding the role of 
oncologists in survivorship care (Cheung et al., 2009). Additionally, the Cheung et al. (2009) 
study identified an overlap in the expectations of oncologists and GPs for survivorship care, 
particularly in regards to follow-up, screening for other cancers and general preventive 
healthcare.  
While this study highlighted the discrepancies between the expectations of cancer 
survivors, GPs and oncologists for survivorship care, the survey primarily concentrated on 
the areas of follow-up, screening for others cancer, preventive healthcare and management of 
comorbidities as a result of cancer diagnosis and treatment. Thus, future research should 
explore the expectations of cancer survivors, GPs and oncologists for survivorship care, 
particularly in the areas of advocacy, support and psychosocial care (Cheung et al., 2009). 
Furthermore, the majority of research on cancer survivorship has occurred in the United 
States to date, and future exploration in the Australian context is needed to explore the 
challenges faced by Australian cancer survivors in the survivorship phase (Jefford et al., 
2008).           
Ambiguity regarding the roles of the varying health professions involved in 
survivorship care has previously led to cancer survivors being ill-informed of the potential 
challenges associated with the survivorship phase, and subsequently ill-equipped to 
proactively manage their own survivorship care (Hewitt et al., 2005). Thus, it has been 
suggested that greater communication between cancer survivors, oncology specialists and 
other treating health professionals is critical for the provision of comprehensive survivorship 
care (Cheung et al., 2009; Mao et al., 2009). 
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Empowering Cancer Survivors Through Communication 
Throughout the continuum of cancer care, patient-clinician communication serves as a 
means for fostering healing relationships, exchanging information, responding to emotions, 
managing uncertainty, making decisions and enabling patient self-management (Epstein & 
Street, 2007). Findings of a systematic review demonstrated the effectiveness of open and 
timely communication on the part of treating health professionals, particularly for decision 
making, compliance and overall satisfaction with cancer care (Rodin et al., 2009). The review 
also highlighted the benefits of honest, empathetic communication in assisting cancer 
survivors and their families to cope with the distress of a diagnosis and the burden of 
treatment (Rodin et al., 2009).  
In addition to enhancing health outcomes for cancer survivors, effective 
communication elicited by treating health professionals is essential for the delivery of true 
patient-centred care (Levinson, Lesser & Epstein, 2010). The Institute of Medicine (IOM) 
describes patient-centred care as “a partnership among practitioners, patients, and their 
families (when appropriate) to ensure that decisions respect patient’s wants, needs, and 
preferences and that patients have the education and support they need to make decisions and 
participate in their own care” (IOM, 2001b, p.7).  
In a qualitative study exploring the perceptions of cancer survivors on patient-centred 
care, participants felt that empowerment through respect, honest information sharing and 
open communication, and shared decision making about treatment plans with oncology 
specialists were important features of patient-centred cancer care (Kvåle & Bondevik, 2008). 
Notably, while participants expressed a desire to be involved in decision making, it was felt 
that oncology specialists should make the final decisions regarding treatment. This study 
highlights the importance of patient-clinician communication in order to determine patients’ 
desires to be involved in their care, and to what extent, for the provision of patient-centred 
cancer care across the entire cancer trajectory (Kvåle & Bondevik, 2008).      
Survivorship Care Plans 
Communication is critical for the ongoing coordination of cancer survivors’ long-term 
care (Hewitt et al., 2005). In the report From Cancer Patient to Cancer Survivor: Lost in 
Transition, Hewitt et al. (2005) strongly recommended that cancer survivors and their GPs 
receive a survivorship care plan (SCP) by the primary treating oncologist at the completion of 
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treatment. The SCP should include a treatment summary (including the potential long-term 
sequelae as a result of treatment), plan for follow-up (including frequency and recommended 
content to be addressed during follow-up appointments), and information regarding health 
promotion strategies and psychosocial support services available in the community (Hewitt et 
al., 2005).  
SCPs can empower cancer survivors to assume an active role in their long-term care, 
and thus promote patient-centred cancer care (Ganz & Hahn, 2008; Hewitt et al., 2005). 
Additionally, these plans can enhance communication between oncology specialists, GPs and 
cancer survivors, and ultimately foster a shared understanding of the specific roles and 
responsibilities of treating health professionals for the effective coordination of cancer 
survivors’ long-term care (Dulko et al., 2013). In doing so, SCPs can alleviate the concerns of 
cancer survivors when transitioning from active treatment to the survivorship phase of the 
cancer care continuum (Haq et al., 2013).      
Despite the recognised benefits of SCPs in the coordination of cancer survivors’ 
ongoing care post-treatment, recent studies indicate a number of barriers in the effective 
implementation of SCPs in everyday practice. Establishing SCPs for cancer survivors and 
their GPs is time consuming, and as a result, oncologists may be reluctant in completing this 
lengthy document (Haq et al., 2013; Hewitt, Bamundo, Day & Harvey, 2007).  
A cross-sectional survey was conducted to explore the attitudes of health 
professionals practising in Australia regarding the use of SCPs for breast cancer follow-up 
care (Brennan, Butow, Spillane & Boyle, 2010). 51% of oncology specialists, 83% of breast 
physicians and 92% of breast care nurses felt that SCPs would improve survivorship care for 
breast cancer survivors (Brennan et al., 2010). Time required to complete SCPs was a 
concern for some participants (Brennan et al., 2010). While this study demonstrates health 
professionals’ support of SCPs in Australian cancer care, the lower percentage of oncologists 
in favour of this follow-up plan may support previous research findings that demonstrate 
oncologists’ perceived barriers to completing SCPs (Haq et al., 2013; Hewitt, Bamundo, Day 
& Harvey, 2007). Ongoing education regarding the benefits of SCPs and the adoption of 
electronic medical record systems may assist oncologists in carrying out this important task 
for the provision of high quality survivorship care (Hewitt et al., 2007). Additionally, it is 
recommended that this service be reimbursed by third-party payers to health care, such as 
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Medicare Australia and private health insurance funds, given the time oncologists would need 
to delegate to completing SCPs (Hewitt et al., 2007).   
The survivorship phase represents an immensely personal and challenging time for 
cancer survivors, their families, caregivers and friends. The implementation of effective 
communication channels between health professionals and their patients can contribute to 
improved health outcomes, and ensure cancer care reflects a patient-centred approach (Hewitt 
et al., 2005; Venetis, Robinson, Turkiewicz & Allen, 2009). Thus, patient-centred 
communication and the use of SCPs can raise awareness of the long-term sequelae 
experienced by cancer survivors as a result of a cancer experience.  
 
The Lasting Effects of a Cancer Experience 
The long-term and late effects of cancer and its treatment can have a lasting impact on 
a cancer survivor’s QOL (Stein, Syrjala & Andrykowski, 2008; Zebrack, Yi, Petersen & 
Ganz, 2008). Long-term effects are usually defined as the physical and psychological 
implications that develop during the treatment phase and continue for at least five years post-
treatment (Stein, et al., 2008). Alternatively, late effects are not present during treatment but 
develop in the survivorship phase as a delayed outcome of treatment (Stein, et al., 2008). 
Physical long-term and late effects of treatment, such as reduced muscle strength, 
stamina and mobility can restrict cancer survivors’ participation in meaningful everyday 
activities (Ness, Wall, Oakes, Robison & Gurney, 2006). Additionally, problems with sexual 
functioning, fatigue, osteoporosis and weight gain are lasting implications of cancer and its 
treatment, which can impact upon a cancer survivor’s daily function and QOL (Frumovitz et 
al., 2005; Miller et al., 2005; Partridge & Winer, 2004; Potosky, 2004; Schultz, Klein, Beck, 
Stava, & Sellin, 2005). 
Psychological long-term and late effects due to a cancer experience, such as anxiety 
and depression, can be difficult to determine given their prevalence within the general 
population (Stein, et al., 2008). Nonetheless, cancer survivors have expressed feelings of 
chronic unhappiness and distress well into the survivorship phase. This may be attributed to a 
cancer diagnosis and the burden of treatment, in addition to fear of a new primary cancer 
diagnosis or recurrence (Deimling, Bowman, Sterns, Wagner & Kahana, 2006; Hodgkinson 
et al., 2007; Schultz et al., 2005).  
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In contrast, some cancer survivors report positive outcomes of their cancer 
experience, such as personal growth and greater appreciation for life (Bower et al., 2005; 
Hodgkinson et al., 2007). Nonetheless, the long-term challenges faced by cancer survivors 
are significant and if not appropriately managed, can ultimately diminish a person’s QOL; 
further emphasising the need for collaboration between treating health professionals and their 
patients for the coordination of survivorship care (Hewitt et al., 2005).     
      
Cognitive Changes Associated With a Cancer Experience 
Subtle changes to cognition are widely acknowledged as an issue present during the 
survivorship phase (Vardy, Wefel, Ahles, Tannock & Schagen, 2008). Changes in the 
cognitive domains of information and processing speed, attention, memory retrieval and 
executive function are commonly reported by cancer survivors throughout the continuum of 
cancer care (Vardy et al., 2008; Wagner, Sweet, Butt, Lai & Cella, 2009). While this 
phenomenon has received growing attention in the literature, particularly with regards to 
cancer survivorship, the explicit cause of cognitive changes remains unknown (Selamat, Loh, 
Mackenzie & Vardy, 2014).    
Cognitive Changes as a Result of Chemotherapy Treatment 
‘Chemobrain’ or ‘chemofog’ are common terms used by cancers survivors, health 
professionals and researchers to describe subtle cognitive changes as a result of 
chemotherapy treatment (Argyriou, Assimakopoulos, Iconomou, Giannakopoulou & 
Kalofonos, 2011). Cognitive changes may be due to hormonal imbalances and the toxic 
effects that chemotherapeutic agents can have on the brain (Christie et al., 2012; McAllister 
et al., 2004). Furthermore, cognitive changes as a result of chemotherapy may be further 
exacerbated by anxiety, depression and fatigue (McAllister et al., 2004)     
Prospective longitudinal studies have found that standard-dose and high-dose   
chemotherapy treatment can cause subtle changes in cancer survivors’ cognition during and 
after treatment (Schagen, Muller, Boogerd, Mellenbergh & van Dam, 2006; Wefel, Lenzi, 
Theriault, Davis & Meyers, 2004). Schagen et al. (2006) examined changes in cognitive 
function as a result of standard-dose and high-dose chemotherapy amongst breast cancer 
survivors. The study found that a greater number of participants who received high-dose 
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chemotherapy experienced a decline in cognitive performance compared to participants who 
received standard-dose chemotherapy (Schagen et al., 2006).  
Alternatively, a prospective study evaluating the effects of standard-dose 
chemotherapy on breast cancer survivors’ cognition found that only a small proportion of 
participants experienced a decline in concentration and memory, and the majority remained 
unaffected or improved over time (Jenkins et al., 2006). Participants who had experienced a 
decline in cognitive performance also experienced treatment-induced menopause, suggesting 
that a reduction in oestrogen may exacerbate cognitive changes or even effect cognition 
independently of chemotherapeutic agents (Jenkins et al., 2006).  
Though research has mainly concentrated on breast cancer populations, preliminary 
evidence suggests that survivors diagnosed with other cancers such as ovarian cancer (Correa 
& Hess, 2012) and testicular cancer (Schagen et al., 2008) may also experience cognitive 
changes as a result of chemotherapy. Thus, a need exists for robust, longitudinal studies in 
tumour groups other than breast cancer to determine and compare prevalence and severity of 
cognitive changes between tumour groups as a result of treatment (Janelsins, Kesler, Ahles & 
Morrow, 2014).  
Cognitive Changes as a Result of a Cancer Diagnosis  
While research has largely focused on the effects of chemotherapy on cognition after 
treatment, a small number of prospective longitudinal studies have evaluated the cognitive 
functioning of cancer survivors pre-chemotherapy and post-chemotherapy (Hermelink et al., 
2007; Jansen, Cooper, Dodd & Miaskowski, 2011; Wefel et al., 2004). Assessment of 
participants’ cognition at the pre-chemotherapy stage found that a proportion of cancer 
survivors are experiencing subtle changes in cognitive performance prior to the 
commencement of chemotherapy, which are unrelated to anxiety or depression (Hermelink et 
al., 2007; Jansen et al., 2011; Wefel et al., 2004).  
In one prospective randomised longitudinal trial, approximately 33% of breast cancer 
survivors demonstrated reduced cognitive function prior to receiving chemotherapy (Wefel et 
al., 2004). The study revealed pre-chemotherapy decline in cognition relating to attention, 
learning and processing speed (Wefel et al., 2004). While the study’s sample size was 
relatively small (n = 18), it was the first known published trial to examine cognitive changes 
at the pre-chemotherapy and post-chemotherapy stages using a longitudinal design. Pre-
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treatment cognitive changes in cancer survivors may be due to factors relating to the disease 
itself such as the production of pro-inflammatory cytokine levels in the brain, which may 
subsequently lead to disruptions in cognitive function (Meyers, Albitar & Estey, 2005; 
Seruga, Zhang, Bernstein & Tannock, 2008; Vardy et al., 2007).  
Cognitive Changes as a Result of Other Confounding Factors 
Various personal factors may influence a cancer survivor’s cognitive function 
throughout the cancer trajectory, including age, education, genetics and treatment-induced 
menopause (Ahles & Saykin, 2007; McAllister et al., 2004). Additionally, psychological and 
physical implications as a result of a cancer diagnosis and the burden of treatment, such as 
anxiety, depression and fatigue can influence a cancer survivor’s perceived cognitive deficits 
(Ahles & Saykin, 2007; Biglia et al., 2012; Jansen et al., 2011; McAllister et al., 2004; 
Pullens, De Vries & Roukema, 2010).                
In recent years, research has explored the association between self-perceived 
cognitive deficits and neuropsychological impairment in cancer survivors. While negative 
emotional functioning can impact how a survivor judges their cognitive performance, 
prospective studies have found that self-perceived cognitive deficits do not correlate with 
neuropsychological assessment outcomes (Biglia et al., 2012; Hermelink et al., 2010; Skaali 
et al., 2011). Nonetheless, a cancer survivor’s perceived cognitive deficits can impact 
participation in meaningful, everyday activities and ultimately hinder their QOL beyond the 
survivorship phase (Burgess et al., 2005; Mehnert, 2007; Shilling & Jenkins, 2007). 
While the explicit cause of cognitive changes in cancer survivors remains unknown, 
Vardy et al. (2008) suggest these changes are likely multifactorial; brought about by the 
complex relationship between the disease, its treatments and an individual’s unique personal 
factors. Regardless of aetiology, cognitive changes can have a serious effect on the health and 
well-being of cancer survivors.    
 
Associations Between Cognitive Changes, Daily Function and Quality of Life 
 Though largely subtle in nature, cognitive changes as a result of a cancer diagnosis 
and treatment can have a profound impact on a person’s daily functioning and overall QOL 
(Lauver, Connolly-Nelson & Vang, 2007; Munir et al., 2011; Tannock, Ahles, Ganz & van 
Dam, 2004; Wefel et al., 2004). Diminished functional ability can impede a cancer survivor’s 
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transition back to work (Bradley, Neumark, Bednarek & Schenk, 2005; Duijts, 2014), 
community engagement (Reid-Arndt, Yee, Perry & Hsieh, 2009) and participation in 
meaningful activities, such as driving and reading (Myers, 2012).       
In a qualitative exploratory study that investigated the long-term side effects of 
chemotherapy for breast cancer survivors, cognitive changes were one of the most commonly 
documented chronic symptoms by participants (Boykoff, Moieni & Subramanian, 2009). 
Participants reported feeling fearful and saddened that they were no longer able to retain new 
information like they once could; leading to a sense of hopelessness and diminished self-
efficacy. Furthermore, participants claimed they were unable to fulfil pre-existing roles 
within their personal, professional and social environments as a result of cognitive changes. 
Consequently, participants could not perform meaningful activities independently, which 
hindered their overall health and well-being (Boykoff et al., 2009). 
In a recent qualitative descriptive study, breast cancer survivors expressed feeling 
frustrated by self-perceived cognitive deficits (Von Ah, Habermann, Carpenter & Schneider, 
2013). Furthermore, participants reported a decline in self-confidence, social relationships 
and their ability to perform work duties to the same level that they were once use to as a 
result of perceived cognitive deficits (Von Ah et al., 2013). This study also highlighted the 
needs of cancer survivors to have their cognitive concerns validated and supported by family, 
friends and healthcare providers (Von Ah et al., 2013). 
 
Rehabilitation and Management of Cancer-Related Cognitive Changes  
Despite the lasting impacts of cognitive changes, there appears to be a lack of 
information provided to cancer survivors regarding the potential for cognitive changes as a 
result of a cancer experience (Mitchell & Turton, 2011). In an exploratory study, breast 
cancer survivors and oncology health professionals were interviewed to identify the degree of 
information available to patients regarding the possible side effects of chemotherapy (Munir 
et al., 2011). While all participants reported to have received information about the physical 
side effects of treatment, discussions around cognitive changes were generally patient-led or 
not addressed at all (Munir et al., 2011). This was supported by the responses of health 
professionals, who acknowledged the lack of information provided to patients regarding the 
possibility of cognitive changes. This study highlighted the uncertainty of health 
professionals regarding the management of patients’ cognitive concerns. Additionally, the 
Section I: Literature Review 23 
 
study emphasised the need for future research in order to identify evidence-based 
interventions for the treatment of subtle cognitive changes as a result of a cancer experience 
(Munir et al., 2011).     
In the Boykoff et al. (2009) study, a large proportion of participants reported having 
their cognitive concerns dismissed by treating health professionals. According to the self-
reports of participants, oncologists provided little to no warning prior to commencing 
chemotherapy, and would frequently blame confounding factors such as age when patients 
raised the issue of cognitive changes (Boykoff et al., 2009). This lack of validation left cancer 
survivors feeling frustrated and scared; ultimately impacting on their QOL (Boykoff et al., 
2009). While a small subset of participants did receive validation when raising their cognitive 
concerns to health professionals, participants acknowledged the lack of management 
guidelines for the treatment of CRCC (Boykoff et al., 2009). Additionally, many participants 
expressed a desire to be informed about the possibility for CRCC pre-treatment, and felt that 
being forewarned by oncologists would assist in coping with this potential symptom of 
treatment (Boykoff et al., 2009).  
A cross-sectional survey was conducted to better understand the perceptions of 
oncologists, nurses, and pharmacists practising in Asia regarding the significance, effects and 
potential causes of cognitive changes following cancer diagnosis or treatment. Of all 
participants (n = 193), oncologists were less likely to identify chemotherapy as the leading 
cause for cognitive changes in patients (Cheung et al., 2013). Approximately half of the 
respondents claimed that patients seldom raised the issue of cognitive changes. Cheung et al. 
(2013) suggest that this inconsistency in the study’s findings may support previous research, 
which indicates that oncologists do not specifically address this potential side effect of a 
cancer diagnosis or treatment with their patients (Boykoff et al., 2009; Munir et al., 2011). 
However, further exploration is needed into why oncologists do not generally inform patients 
of the possibility of CRCC.  
Cheung et al.’s (2013) study is the first known published study to examine the 
perceptions of oncology health professionals regarding the phenomenon of subtle cognitive 
changes and its effects on cancer survivors. As this study collectively examined the 
perceptions of Asian oncology health professionals, future research using individual group 
sampling would assist in identifying similarities and differences in perceptions amongst the 
varying healthcare professions involved in survivorship care (Cheung et al., 2013). 
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Additionally, future research within a westernised context would account for the contrasting 
features of western and eastern cultures in a healthcare setting.      
 
Conclusion 
The subtle cognitive changes experienced by cancer survivors following cancer 
diagnosis and treatment are becoming increasingly acknowledged within the oncology 
community as a survivorship issue. Self-reports of cancer survivors demonstrate the profound 
impact that changes in cognition can have on QOL. Nonetheless, research identifies a gap in 
oncology specialists’ practice in providing consultation and support to cancer survivors 
regarding the possible changes to cognition following cancer diagnosis and treatment. As a 
result, cancer survivors report feeling disempowered, ill-informed of the potential, long-term 
implications of CRCC, and subsequently ill-equipped to assume a proactive role in their 
survivorship care. While previous research demonstrates oncology specialists’ awareness of 
this phenomenon and the lack of information provided to cancer survivors regarding CRCC, 
factors influencing this limitation in oncology specialists’ practice remains unexplored in the 
literature. Consequently, the cognitive concerns of cancer survivors are often dismissed, 
impeding the likelihood of multidisciplinary collaboration for the holistic management of 
CRCC and their effects on cancer survivors’ daily functioning and QOL.   
 
Recommendations for Future Research 
Understanding the reasons why discussions around CRCC are generally initiated by 
cancer survivors or not addressed at all remains unclear in the current body of research. What 
is known is that discussions between oncologists and patients regarding the potential effects 
of treatment on cognition are rare, particularly when compared with informing cancer 
survivors of the physical side effects of cancer diagnosis and treatment. Thus, there is a need 
to explore the perceptions of oncologists regarding their understandings and practice around 
CRCC, and how their views may influence decisions about patient care. In doing so, possible 
barriers to best practice can be identified and addressed in order to support the provision of 
patient-centred cancer care.  
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Accordingly, the subsequent study aims to employ qualitative methods to address the 
following research questions: 
 How do oncologists perceive cognitive changes and the underlying cause(s) in 
cancer survivors following diagnosis and treatment? 
 How do oncologists anticipate and address cognitive changes with their patients 
across the continuum of cancer care, including the survivorship phase? 
 
Significance and Scope of the Study 
This study does not explicitly seek to prove or disprove existing research regarding 
the cause of cognitive changes in cancer survivors. Instead, the objective of the study is to 
explore Australian oncologists’ understandings of the cognitive changes experienced by 
survivors as a result of a cancer diagnosis and treatment, and how their views may influence 
decisions about patient care.  The findings of this study will contribute to an understanding of 
how to address the need for specific interventions and management guidelines addressing 
CRCC and their effects on cancer survivors to assist oncologists in their practice. It is also 
hoped that study findings will raise awareness of referral options for Australian oncologists to 
other health professionals who can provide rehabilitation services to help manage and 
overcome CRCC for cancer survivors. Shedding light on this under-addressed aspect of 
oncology practice places the needs of the cancer survivor as central to their care, and should 
foster a more holistic approach to the management of CRCC by involving all members of the 
multidisciplinary team.   
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Abstract 
Objective: Cancer related cognitive changes (CRCC) can have a profound impact on a cancer 
survivor’s quality of life. Nonetheless, cancer survivors report receiving limited information 
by oncology specialists regarding this phenomenon. This qualitative study aimed to explore 
the perceptions of oncology specialists regarding CRCC, and how their views may influence 
decisions about patient care.    
Methods: Thirteen medical oncologists and five radiation oncologists currently practising in 
Australia participated in this study. Data collection involved individual, semi-structured 
interviews via telephone. Data were audio-recorded, transcribed verbatim and analysed using 
a thematic approach.   
Results: Four key themes emerged: (1) Beliefs about the impact of priming on cancer 
survivors’ perceived cognitive function (2) Perceptions of who is more likely to raise 
concerns of cognitive change (3) Uncertainty of how to best manage CRCC (4) Oncologists’ 
perceived role in the management of CRCC  
Conclusions: CRCC and its impact on the cancer survivor’s journey has been under-
addressed by oncology specialists, and they are uncertain of potential management strategies. 
With cancer survival rates increasing, there is a need for specific interventions and 
management guidelines addressing CRCC and their effects on cancer survivors. Future 
exploration should focus on the survivor as central to their care, and holistic approaches to 
CRCC management involving all members of the multidisciplinary team.   
Key words: cancer, oncology, cognition, survivorship, clinical practice, qualitative 
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The Perceptions of Australian Oncologists Regarding Cognitive Changes in Cancer 
Survivors  
 
Introduction 
One in two Australians will be diagnosed with cancer during their lifetime [1]. While 
cancer prevalence in Australia has increased, so have five-year survival rates for people 
diagnosed with cancer [1]. As survivorship becomes increasingly recognised as a distinct 
phase of cancer care, uncertainty has emerged regarding the roles and responsibilities of those 
caring for cancer survivors [2-4]. In a study by Cheung et al. [2], cancer survivors were found 
to have higher expectations than oncologists regarding the role of oncologists in survivorship 
care. Additionally, the study identified an overlap in the expectations of oncologists and 
general practitioners (GPs) for survivorship care, particularly regarding follow-up, screening 
for other cancers and preventive healthcare [2]. The gaps in survivorship care have previously 
led to cancer survivors being ill-informed of the potential challenges associated with the 
survivorship phase [5].  
Subtle changes to cognition are widely acknowledged as an issue present during the 
survivorship phase [6], and can impact daily functioning and quality of life (QOL) [7]. 
Changes in the cognitive domains of information and processing speed, attention, memory 
retrieval and executive function are commonly reported by cancer survivors along the 
continuum of cancer care [6]. While this phenomenon has received growing attention in the 
literature, the explicit cause of cognitive changes remains unknown [8].  
‘Chemobrain’ or ‘chemofog’ are common terms used to describe subtle cognitive 
changes as a result of chemotherapy treatment [9]. Cognitive changes may be due to 
hormonal imbalances and the toxic effects that chemotherapeutic agents can have on the 
brain [10]. A small number of prospective longitudinal studies have evaluated the cognitive 
functioning of cancer survivors pre-chemotherapy and post-chemotherapy, and found that a 
proportion of cancer survivors are experiencing cognitive changes prior to commencing 
chemotherapy [11-13]. Pre-treatment cognitive changes may be due to factors relating to the 
disease itself such as the production of pro-inflammatory cytokine levels in the brain [14]. 
Various personal factors may also influence a cancer survivor’s cognitive function 
throughout the cancer trajectory, including age, education, genetics and treatment-induced 
menopause [10, 15]. Additionally, psychological and physical implications as a result of a 
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cancer diagnosis and the burden of treatment, such as anxiety, depression and fatigue can 
influence a cancer survivor’s cognitive function [10, 12, 15, 16].While negative emotional 
functioning can impact how a survivor judges their cognitive performance, prospective 
studies have found that self-perceived cognitive deficits do not correlate with 
neuropsychological assessment outcomes [11, 16, 17]. However, self-reports of cancer 
survivors highlight the impact of perceived cognitive deficits on overall health and well-being 
[18, 19]. 
Despite the lasting impacts of cancer-related cognitive changes (CRCC), there 
appears to be a lack of information provided to cancer survivors regarding the possibility of 
cognitive changes following cancer diagnosis and treatment [20]. In a study by Boykoff et al. 
[18], a large proportion of participants reported having their cognitive concerns dismissed by 
oncologists and were provided little to no warning prior to commencing chemotherapy. This 
lack of validation left cancer survivors feeling frustrated and scared; ultimately impacting on 
their QOL [18]. A recent study explored the perceptions of oncologists, nurses, and 
pharmacists practising in Asia regarding CRCC [21]. Approximately half of the oncologists 
in the study claimed that patients seldom raised the issue of cognitive changes. These 
findings may support previous research, which indicate that oncologists do not specifically 
address this potential side effect of a cancer diagnosis or treatment with their patients [18, 
22].   
Reasons why the discussion around CRCC is generally initiated by cancer survivors 
or not addressed at all remains unclear in the current body of research. What is known is that 
discussions between patients and oncologists regarding the potential effects of treatment on 
cognition are rare, leaving patients feeling isolated and disempowered. This research asks:  
 How do oncologists perceive CRCC and the underlying cause(s) in cancer 
survivors? 
 How do oncologists anticipate and address CRCC with their patients across the 
continuum of cancer care, including the survivorship phase? 
The aim of this study was to explore the perceptions of Australian oncologists 
regarding CRCC, and how their views may influence decisions about patient care.  
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Methods 
Study Approach 
This study adopted a qualitative approach using thematic analysis [23]. A thematic 
approach can foster insightful findings addressing research questions that seek to identify 
values, perceptions and experiences [23], such as exploring oncology specialists’ perceptions 
of cognitive changes in cancer survivors.   
Ethics approval was obtained from the Human Research Ethics Committee at the 
University of Sydney, Australia (Reference no. 2014/323).  
Sampling and Recruitment 
Medical and radiation oncologists currently practising in Australia were eligible to 
participate in the study. Participants were recruited through advertisements that were 
distributed via email by membership organisations within the oncology community.  The 
advertisement invited members to complete an online Expression of Interest if willing to 
participate in the study. The purpose of the Expression of Interest was to collect participants’ 
demographic information to enable stratification of the sample if possible, availability for 
interview, and gaining informed consent.  
Snowballing was also used in recruitment in an attempt to maximise participation by a 
group with a known, low response rate due to existing priorities in everyday practice [24] 
Data Collection 
Data collection involved individual, telephone interviews. Interviewing via telephone 
rather than face-to-face was selected due to likely constraints regarding time and location for 
participants. A semi-structured interview schedule (see Appendix B) was used for all 
interviews to enable information sharing and knowledge building [25]. Prior to commencing 
interviews, participants provided verbal consent for interviews to be audio-recorded and 
transcribed verbatim. Interviews lasted between 15 and 30 minutes.  
Data Analysis 
In keeping with Braun and Clarke’s guidelines for a rigorous thematic approach, six 
phases of analysis were applied: 1. Familiarisation with the data, 2. Generating initial codes, 
3. Searching for themes, 4. Reviewing themes, 5. Defining and naming themes and 6. Writing 
the report [23]. An inductive approach to coding was performed during the data analysis 
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phase, where the data drove the coding process as opposed to coding data using a pre-existing 
framework [23].     
In addition to transcribing thirteen of the eighteen interviews, the first author 
repeatedly read each of the transcripts. Initial codes were then generated from the data and 
organised into potential, broader themes that signified meaning and were relevant to the 
research questions.  
Rigour  
A number of strategies were employed to enhance the study’s rigour. The first author 
used a journal to document their thoughts and interactions during and directly after 
interviews. This enabled reflexivity, and the ability to distinguish between personal values 
and assumptions and the true perspectives of participants [26]. Member checking was used to 
ensure accuracy of data [26]. Transcripts were sent to participants for the opportunity to edit 
responses. No participant requested any changes to be made. Throughout data analysis, 
consensus coding was conducted by three of the authors (Smidt, Mackenzie & Dhillon). 
Authors coded data separately then discussed similarities and differences between individual 
analyses and resolved any issues. Potential themes were then reviewed and refined before 
authors identified four key themes. Peer debriefing occurred throughout the research process. 
The second and third authors provided ongoing feedback to the first author, ensuring the 
reported interpretations and conclusions were true representations of the data set.   
 
Results  
Participants  
Thirteen medical oncologists and five radiation oncologists participated in the study 
(Table 1). Most participants were aged 35-44, male and practised within the Australian public 
hospital system. Participants subspecialised in a range of cancer groups. 
While participants had varying perceptions of CRCC, four key themes emerged from 
the interview data: (1) Beliefs about the impact of priming on cancer survivors’ perceived 
cognitive function (2) Perceptions of who is more likely to raise concerns of cognitive change 
(3) Uncertainty of how to best manage CRCC (4) Oncology specialists’ perceived role in the 
management of CRCC (Table 2).     
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Table 1 
Participant Demographics 
Participant 
no. 
State 
Geographical 
Location 
Gender 
Age 
Range 
Institution 
of Primary 
Practice 
Oncology 
Discipline 
Sub-Specialty 
1 QLD Metropolitan Male 65-74 Mixed Medical Breast 
2 NSW Regional Female 35-44 Public Radiation 
Gastro-Intestinal, 
Head & Neck, Brain 
3 VIC Metropolitan Male 45-54 Public Medical 
Breast, 
Genitourinary, Brain 
4 NT Rural Male 35-44 Public Radiation Nil 
5 VIC Metropolitan Male 35-44 Public Medical 
Breast, Gastro-
Intestinal, Lung 
6 QLD Metropolitan Female 35-44 Public Medical Lung, Brain 
7 QLD Metropolitan Male 45-54 Private Radiation Genitourinary 
8 VIC Metropolitan Female 45-54 Public Medical 
Breast, 
Genitourinary, Lung 
9 WA Metropolitan Male 45-54 Public Medical 
Breast, 
Genitourinary 
10 VIC Regional Male 35-44 Public Medical Nil 
11 WA 
Regional & 
Rural Male 35-44 Public Radiation Nil 
12 QLD Metropolitan Male 55-64 Mixed Medical 
Gastro-Intestinal, 
Melanoma 
13 NSW Regional Male 25-34 Public Medical Breast 
14 NSW Metropolitan Male 35-44 Public Medical 
Gastro-Intestinal, 
Lung, Melanoma 
15 VIC Metropolitan Female 35-44 Public Medical 
Gastro-Intestinal, 
Lung 
16 SA Metropolitan Male 35-44 Mixed Medical 
Genitourinary, 
Gynaecological, 
Brain, Sarcoma 
17 NSW Metropolitan Female 45-54 Mixed Medical 
Breast, Gastro-
Intestinal 
18 ACT Metropolitan Female 45-54 Public Radiation 
Genitourinary, Head 
& Neck, Sarcoma, 
Melanoma 
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Table 2 
 
Themes and Sample Codes 
 
   
 
 
Themes Sample Codes 
 
 
 
1. Beliefs about the impact 
of priming on cancer 
survivors’ perceived 
cognitive function 
- Higher rates of self-reports by breast cancer survivors 
(BCS) 
- Online forums, support groups influence perceived 
cognitive deficits (PCD) 
- Informing patients of CRCC pre-treatment may contribute 
to increased self-reports 
- Hesitant to initiate discussion due to priming effect 
- More likely to initiate discussion with BCS due to priming 
effect 
- Dissociation between PCD and measurable cognitive 
impairment  
  
 
 
2. Perceptions of who is 
more likely to raise 
concerns of cognitive 
change 
- Younger females 
- Older Adults 
- Cognitively demanding work roles 
- Cancer survivors receiving chemotherapy, radiotherapy to 
brain 
- Brain tumour, brain metastases  
- Fatigue 
- Anxiety 
- Depression 
 
 
3. Uncertainty of how to 
best manage CRCC 
- No management guidelines 
- Lack of screening assessments 
- Hesitant to initiate discussion due to uncertainty 
 
 
 
4. Oncology specialists’ 
perceived role in the 
management of CRCC 
- Management of physical side effects 
- Screening for cancer recurrence 
- Health promotion 
- Normalise CRCC 
- Recommend informal tips/coping strategies  
- Referral to GPs, psychologists, other Allied Health 
- Referral for neuropsychological assessment 
- Perceived barriers: lack of post-treatment clinics, financial 
constraints, limited time for follow-up appointments 
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Theme 1: Beliefs about the impact of priming on cancer survivors’ perceived cognitive 
function 
 Many oncology specialists perceived a difference in the frequency of reporting 
cognitive changes between survivors of breast cancer and other cancer groups. This 
difference was believed to be associated with the higher degree of supportive care provided to 
breast cancer survivors across the continuum of cancer care. Online forums, local support 
groups and information provided by not for profit organisations were believed to facilitate 
information sharing and raise awareness regarding the potential for cognitive changes as a 
result of a cancer experience.  
Participant 3: “…there’s so much more literature about it [cognitive change] for 
women out there with breast cancer and support groups… I think the women are more 
aware of this whole chemo fog thing and the effects of chemotherapy in general.” 
[Medical oncologist]  
Participant 14: “I think in, in the breast cancer population this [cognitive change] is 
much more often discussed and you know, I think there are more services that are 
tuned in to help people with breast cancer when they have this problem. But certainly 
in the other tumour streams it [cognitive changes] doesn’t seem to be the same degree 
of interest or reporting or, or recognition that this is a problem.” [Medical 
oncologist]   
The previous experiences and perceptions of participants influenced how they 
anticipated and addressed cognitive changes with their patients. Some participants were 
hesitant to initiate discussions about possible cognitive changes, believing that patients were 
more likely to raise cognitive concerns if their oncologist informed them of this potential side 
effect.   
Participant 1: “I feel that priming is a key issue in all of this. You go into a room and 
give a talk to women then say, ‘who’s got some cognitive changes after 
chemotherapy?’ and everybody puts up their hands. I don’t believe the problem is that 
common… maybe I’m creating the problem… their problem is we’ve got to get them 
back into life again of which cognitive functioning is one of the aspects.” [Medical 
oncologist]   
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In contrast, some participants felt it was important to lead a discussion with breast 
cancer survivors regarding the potential for cognitive changes as a result of chemotherapy. 
Oncologist-led discussions that focussed specifically on cognitive issues aimed to ease the 
concerns of breast cancer survivors due to the heightened awareness within the breast cancer 
community.  
Participant 12: “So [for] the breast cancer population I would tend to talk about it 
more than I do in other groups up front, because I think it’s to try and prevent some of 
the issues. Some of the other groups I don’t think it’s such as issue… I’d talk more 
generally about the effects of treatment, how it might affect your life and how to 
manage that.” [Medical oncologist]   
 
Theme 2: Perceptions of who is more likely to raise concerns of cognitive change  
Most participants perceived the underlying cause of cognitive changes as 
multifactorial, rather than linked to a single treatment modality. Factors thought to contribute 
to changes in cancer survivors’ cognition included method(s) of treatment, associated 
medications, emotional functioning and the level of support available to survivors across the 
continuum of cancer care.  
Participant 4: “…the factors that go in to neurocognitive decline are psychological, 
spiritual, physical, disease-related, treatment-related, environmental. So it’s not 
something that we can say it’s one particular thing. It’s a number of things.” 
[Radiation oncologist]   
Participants distinguished between objective cognitive deficits and patients’ self-
perceived cognitive changes. The measureable effects on cognition as a result of primary 
brain tumours, brain metastases or radiotherapy to the brain were discussed. However, cancer 
survivors’ self-reports of subtle cognitive changes were often thought to be strongly linked to 
other confounding factors, such as fatigue, anxiety and/or depression. 
Participant 10: “But if a patient who has got a background history of psychological 
issues like depression and anxiety, and particularly those patients who have less 
psychosocial support, I feel that these patients… their cancer significantly impacts 
their cognition.” [Medical oncologist]   
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Participant 9: “It [cognitive change] tends to go hand in hand with fatigue, so people 
who get tiredness also get cognitive impairment. People who report no tiredness seem 
to be relatively unimpaired… with fatigue settling, some people come right literally 
within a small number of weeks.” [Medical oncologist]    
Age and gender of cancer survivors were believed to influence reporting of cognitive 
changes. Of the participants who felt these demographics contributed to perceived changes in 
cognition, the majority believed that younger women were more likely to report cognitive 
changes.  
Participant 8: …I have had very little complaint about it [cognitive change] from men. 
It's been largely women… I think that those patients under fifty and around that age, I 
would say, notice it [cognitive change] more.” [Medical oncologist] 
Additionally, participants discussed employment as a contributing factor to self-
perceived cognitive changes.  
Participant 9: “So people in higher end jobs are more likely to notice it. If you're not 
doing a job that requires a high degree of cognitive function, then you’re less likely to 
notice it.” [Medical oncologist]     
As cognitive changes were perceived by some oncologists as downstream effects of 
the cancer experience, they recommended screening for anxiety, depression and fatigue to 
ensure treatable symptoms were not missed.   
 
Theme 3: Uncertainty of how to best manage cancer-related cognitive changes  
While participants felt cognitive changes had received growing attention as a 
survivorship issue, many expressed uncertainty regarding the management of CRCC, largely 
because they believed there were few options available to intervene. This uncertainty 
impeded the likelihood of oncologist-led discussions regarding CRCC.  
Participant 13: “But the difficulty is, is that I don’t really know what to do about it, 
and it’s hard to ask a question that you don’t know the answer to or you don’t know 
the solution to.” [Medical oncologist]      
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Participant 14: “… you can’t really fix it [cognitive changes] for them, and you don’t 
even know how bad it is and you don’t know where to go or anything, so most of the 
time you just end up just watching it and then just sitting on it and maybe even 
forgetting to ask about it the next time anyway. So it’s like one of those things that 
aren’t in my practice first and foremost.” [Medical oncologist]       
Participants attributed their uncertainty to the absence of management guidelines. 
Additionally, participants discussed the challenge of accurately assessing the cognitive 
concerns of patients due to the lack of screening tools designed to measure subtle cognitive 
changes.  In the absence of evidence-based guidelines, the management of patients’ cognitive 
concerns differed amongst participants. Many acknowledged the need for ongoing research 
for the development and provision of specific interventions and management guidelines 
addressing CRCC and their effects on cancer survivors.  
Participant 5: “…guidelines for clinicians would be useful as well, to sort of base 
what I’m doing on best practice and what evidence is out there…” [Medical 
oncologist]  
 
Theme 4: Oncologists’ perceived role in the management of CRCC 
Participants emphasised their curative role across the continuum of cancer care, in 
addition to the management of physical side effects as a result of cancer and its treatments. 
Screening for cancer recurrence was perceived as an important aspect of an oncologist’s role 
within the survivorship phase. Additionally, some participants discussed health promotion as 
a key responsibility of oncologists during the survivorship phase.  
While discussions were often patient-led, some participants raised the potential for 
cognitive changes with their patients as part of the consenting process to treatment.  
Participant 9: “It's part of consenting a patient to treatment. If you're going to give 
chemo you need to know everything it may do, all the things that may happen, 
commonly at least. So we tell people before they make a decision about whether to 
have chemo or not.” [Medical oncologist]       
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The management of patients’ perceived cognitive changes varied amongst 
participants. When addressing cognitive concerns, many participants normalised this 
phenomenon and provided informal strategies to cope with the daily impact of cognitive 
changes.  
Participant 2: “… if you keep doing crosswords and puzzles and things like that in the 
long term because that keeps your brain ticking over and stops this [cognitive 
changes], or slows down the effects that may come on as a result of treatment.” 
[Radiation oncologist]       
Participant 3: “It usually boils down to just practical stuff like, make sure you get 
plenty of rest, don't drink too much coffee, write lists all that sort of stuff.” [Medical 
oncologist]       
Referral to GPs and clinical psychologists was another common approach employed 
by participants in managing the cognitive concerns of patients, particularly if these changes 
were felt to be associated with anxiety or depression. A smaller number of participants 
referred patients to other members of the multidisciplinary team for supportive care, 
including nursing, occupational therapy and social work. Few participants informed patients 
of formal cognitive rehabilitation programs, such as memory clinics. Participants often 
discussed the role of clinical neuropsychologists in assessing measureable cognitive 
impairments. However, the time and resources required to administer neuropsychological 
assessments was perceived as a barrier to referring patients. 
 Participants spoke of the barriers to delivering holistic care across the cancer 
trajectory, including the survivorship phase. For example, one participant discussed the 
potential effectiveness of nurse-led post treatment clinics for the continuing provision of 
support to cancer survivors in the survivorship phase. However, the reason such clinics were 
uncommon within the Australian public hospital system was attributed to financial 
constraints.  Additionally, participants discussed the limited time dedicated to follow-up 
appointments, particularly in public hospitals. As a result, participants felt restricted in their 
ability to delve deeper into the challenges faced by cancer survivors during the survivorship 
phase.  
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Participant 15: “... We get them [cancer survivors] back usually every three months.  
Our job then is to get their scans done and we say to them, look that's good.  Did you 
have any side-effects from the chemotherapy?  No?  Okay fine.  Bye, see you in 
another three months.  So we leave a lot of those things up to the general 
practitioner... I think we delegate some of that responsibility of that holistic aspect of 
their care to the community setting.” [Medical oncologist]  
 
Discussion 
Findings from this study confirm that oncology specialists are faced with cancer 
survivors who experience long-lasting sequelae as a result of their cancer diagnosis and 
treatment. While the Australian healthcare system now classifies many cancers as a chronic 
disease, cancer care offered by oncology specialists often reflects a medical approach and 
may not support patients in taking responsibility for and control of their own care [27].  
Across the continuum of cancer care, one challenge for oncology specialists is patient-
clinician communication, which enables patient self-management and is fundamental for the 
provision of patient-centred cancer care [28].  
However, findings indicate that this does not appear to be translated into everyday 
oncology practice. Particularly for CRCC, cancer survivors report receiving little to no 
information from treating oncologists about this potential side effect of a cancer experience 
[20, 22], and results from this study suggest that discussions regarding CRCC are generally 
patient-initiated or not addressed at all. A number of factors may contribute to these findings, 
such as uncertainty regarding the appropriate management of CRCC. The lack of clinical 
practice guidelines for the treatment of CRCC is a perceived barrier to best practice, and 
consequently, some participants of this study were hesitant to discuss this potential side effect 
with patients. Additionally, uncertainty of participants have resulted in the inconsistent 
management of patients’ cognitive concerns in the past.  
Notably, only a small number of participants in this study discussed the potential for 
CRCC with patients when obtaining informed consent for treatment. As cancer survivors 
have previously expressed their desire to be informed and involved in treatment decision 
making [29], the provision of accurate and transparent information is essential for achieving 
true patient-centred cancer care. Moreover, as cancer survival rates continue to increase, 
patient education can foster health literacy and ultimately enable cancer survivors to assume a 
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proactive role in their long-term cancer care. In keeping with the principles of patient-centred 
cancer care and the ethical requirements of informed consent, cancer survivors need timely, 
balanced information regarding CRCC, its potential duration, cause(s) and recommendations 
for management.   
 Previous research suggests that the effects of priming and pre-existing knowledge 
may contribute to an increased reporting of cognitive concerns by cancer survivors [30]. This 
notion was supported by the perceptions of some participants in this study. These perceptions 
and previous experiences of oncologists may further explain why oncologists are hesitant to 
disclose information to patients regarding this phenomenon as a result of a cancer diagnosis 
or treatment. While priming or informing patients of the possibility of CRCC has been shown 
to elicit a high rate of self-report cognitive changes after chemotherapy, it is unclear if this is 
due to a priming effect or whether it reflects cancer survivors feeling more able to report 
symptoms that are troubling them. Thus, if oncologists do not inform patients of this potential 
side effect, cancer survivors may feel less inclined to raise cognitive concerns [21].  
Oncology specialists in this study felt that information provided by cancer-related 
online forums, support groups and societies contributed to reports of cognitive changes 
amongst cancer survivors. Yet if patients are not receiving information from their 
oncologists, this will be inevitable. The provision of balanced information may diminish the 
significance and likelihood of the priming effect however, future studies in this area of CRCC 
are warranted [30]. Additionally, further research into CRCC is necessary so the diverse 
group of people caring for cancer survivors can deliver accurate, evidence-based information 
to their patients. 
Findings from this study support the belief that CRCC are caused by a multitude of 
factors [6], including treatment modality, the side effects of associated medications and the 
psychological impact of a cancer experience. Consistent with previous studies [11, 17], 
participants perceived a dissociation between cancer survivors’ perceived cognitive changes 
and measurable cognitive impairment. Participants believed that perceived changes in 
cognitive functioning were strongly linked with fatigue, anxiety and/or depression. Previous 
research has demonstrated a correlation between perceived CRCC and negative emotional 
functioning [16], but causal relationship remains unclear. Regardless of the causes of CRCC, 
cancer survivors want their cognitive concerns to be acknowledged and validated by treating 
oncologists in a timely and open manner [18].  
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     Interestingly, a number of participants perceived a greater likelihood in the 
reporting of cognitive concerns amongst cancer survivors in work roles requiring a high level 
of cognitive functioning. While previous studies demonstrate the challenges faced by cancer 
survivors returning to work due to CRCC [31, 32], there is limited evidence to suggest that 
cancer survivors are more likely to notice changes in cognition and subsequently report 
concerns to oncologists if they are in cognitively demanding positions. While cancer 
survivors experiencing CRCC may be unable to maintain productivity at work, the functional 
implications of CRCC are commonly reported by survivors of varying backgrounds and 
experienced across a range of settings [33]. As a result, some cancer survivors are unable to 
satisfactorily participate in a range of everyday activities, including driving [34] and 
community engagement [35].   
Findings from this study highlight the barriers to delivering survivorship care from the 
perspective of Australian oncologists. Participants commonly discussed the minimal time 
assigned to follow-up appointments, particularly within the public healthcare system. This 
underlines the perceived role of oncologists in the survivorship phase, focussed mainly on 
screening for cancer recurrence and the management of physical side effects. In order to build 
the capacity of cancer survivors to take control of their own long-term care, the survivorship 
phase should also include avenues for health promotion, education and for the long-term 
health concerns of patients, including CRCC to be heard and addressed [5]. While 
participants in this study referred patients to GPs and psychologists for the management of 
CRCC, particularly if thought to be linked with anxiety and depression, very few discussed 
the role of other multidisciplinary team members in managing the cognitive concerns of 
cancer survivors. As suggested in previous research [36], the limited understanding of 
specialist roles in cancer care may prevent oncologists referring patients; ultimately limiting 
the provision of high quality survivorship care.   
Cognitive rehabilitation is a growing area of interest in cancer care and there is 
research to suggest that group-based programs may improve cognitive function and overall 
quality of life [37]. Allied health professionals have much to offer in cognitive rehabilitation 
and management of long-term functional and psychological implications of a cancer 
experience [38]. Particularly for CRCC, occupational therapists can apply a holistic approach 
and foster participation in everyday activities through a range of coping skills and 
compensatory strategies [39]. However, oncology specialists tend not to refer for these 
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services. Further research is needed to determine effective interventions in managing the 
cognitive concerns of cancer survivors across the continuum of cancer care.  
 
Scope and Limitations 
This study highlights Australian oncologists’ understandings of CRCC, and how their 
beliefs extend to everyday practice. However, this study has several limitations that must be 
considered when interpreting the study’s findings. The sample size is relatively small. The 
majority of participants were male, aged 35-44 and practised medical oncology within the 
Australian public hospital system in a metropolitan area. Thus, the results of this study may 
not be generalisable to other oncology disciplines, including radiation and surgical, to the 
Australian private hospital system, or to regional and rural areas of Australia. As participants 
were required to volunteer their participation in the study, it can be assumed that participants 
already demonstrated an awareness of CRCC and had a particular interest in this area of 
cancer care. Therefore, volunteer bias may impede the generalisability of the study’s findings 
to the broader community of oncology specialists practising in Australia.   
Additionally, a large subset of participants currently or previously subspecialise(d) in 
breast cancer. The perceptions of participants may reflect a bias towards this cancer group as 
research into CRCC has mainly focussed on breast cancer populations. Future studies could 
benefit from recruiting a larger number of oncology specialists from a range of disciplines 
within the public and private hospital systems. Furthermore, qualitative studies would 
enhance awareness of the barriers to delivering patient-centred cancer care, and ultimately 
call for quality improvement within the Australian healthcare system.  
 
Conclusion 
 As cancer survival rates increase, CRCC has received growing attention as a 
survivorship issue. CRCC can have a profound impact on a person’s daily functioning and 
QOL [7]. Despite the long-term effects of cognitive changes on a cancer survivor’s well-
being, research indicates a gap in information sharing on the part of oncologists [18, 20]. The 
results of this study and other international studies highlight the uncertainty of oncologists 
regarding the appropriate management of CRCC. As a result, this aspect of a cancer 
survivor’s journey is often under-addressed by oncology specialists [22]. Future research is 
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needed to determine evidence-based interventions and clinical practice guidelines for the 
treatment of cancer survivors’ cognitive concerns across the continuum of cancer care.     
In addition to primary cancer follow-up and screening for cancer recurrence, the 
survivorship phase should include avenues for health promotion and management of long-
term sequelae as a result of a cancer experience [5]. The provision of timely and open 
information across the cancer trajectory can lead to improved health outcomes for cancer 
survivors, and ultimately promote a patient-centred approach to cancer care [40]. Future 
exploration should focus on the needs of the cancer survivor as central to their care, and 
should foster a more holistic approach to CRCC management by involving all members of 
the multidisciplinary team. 
 
Acknowledgements 
The Authors thank the participating oncology specialists for sharing their time, thoughts and 
experiences. 
Conflict of Interest 
The Authors have no conflicts of interest to disclose. 
  
Section II: Journal Manuscript 52 
 
References 
1. AIHW  &  AACR. Cancer in Australia 2012: An Overview. AIHW: Canberra; 
2012. 
2. Cheung WY, Neville BA, Cameron DB, Cook EF, Earle CC. Comparisons of 
patient and physician expectations for cancer survivorship care. Journal of 
Clinical Oncology 2009; 27 : 2489-2495. DOI: 10.1200/JCO.2008.20.3232 
3. Mao JJ, Bowman MA, Stricker CT, et al. Delivery of survivorship care by 
primary care physicians: The perspective of breast cancer patients. Journal of 
Clinical Oncology 2009; 27 : 933-938. DOI: 10.1200/JCO.2008.18.0679 
4. Nissen MJ, Beran MS, Lee MW, Mehta SR, Pine DA, Swenson KK. Views of 
primary care providers on follow-up care of cancer patients. Family Medicine 
2007; 39 : 477-482.  
5. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in 
transition. National Academic Press: Washington, DC, 2005 
6. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy 
related cognitive dysfunction: An international perspective from the Venice 
cognitive workshop. Annals of Oncology 2008; 19 : 623-629. DOI: 
10.1093/annonc/mdm500 
7. Mehnert A, Scherwath A, Schirmer L, et al. The association between 
neuropsychological impairment, self-perceived cognitive deficits, fatigue and 
health related quality of life in breast cancer survivors following standard adjuvant 
versus high-dose chemotherapy. Patient Education and Counseling 2007; 66 : 
108-118. DOI: 10.1016/j.pec.2006.11.005 
8. Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast 
cancer survivors: A meta-ethnography study investigating research and care 
implications. Public Library of Science One 2014; 9 : e108002. DOI: 
10.1371/journal.pone.0108002 
9. Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos 
HP. Either called “Chemobrain” or “Chemofog,” the long-term chemotherapy-
induced cognitive decline in cancer survivors is real. Journal of Pain and 
Symptom Management 2011; 41 : 126-139. DOI: 
10.1016/j.jpainsymman.2010.04.021 
10. McAllister TW, Ahles TA, Saykin AJ, et al. Cognitive effects of cytotoxic cancer 
chemotherapy: Predisposing risk factors and potential treatments. Current 
Psychiatry Reports 2004; 6 : 364-371. DOI: 10.1007/s11920-004-0023-y 
11. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant 
chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal 
study. Cancer 2007; 109 : 1905-1913. DOI: 10.1002/cncr.22610 
12. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal 
study of chemotherapy-induced cognitive changes in breast cancer patients. 
Supportive Care in Cancer 2011; 19 : 1647-1656. DOI: 10.1007/s00520-010-
0997-4 
13. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae 
of standard‐dose adjuvant chemotherapy in women with breast carcinoma: Results 
of a prospective, randomized, longitudinal trial. Cancer 2004; 100 : 2292-2299. 
DOI: 10.1002/cncr.20272 
Section II: Journal Manuscript 53 
 
14. Vardy J, Booth C, Pond GR, et al. Cytokine levels in patients (pts) with colorectal 
cancer and breast cancer and their relationship to fatigue and cognitive 
function. Journal of Clinical Oncology 2007; 25 : 9070. 
15. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive 
changes. Nature Reviews Cancer 2007; 7 : 192-201. DOI: 10.1038/nrc2073 
16. Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive 
dysfunction in breast cancer women treated with chemotherapy: A prospective 
study. European Journal of Cancer Care 2012; 21 : 485-492. DOI: 
10.1111/j.1365-2354.2011.01320.x 
17. Skaali T, Fossa SD, Andersson S, et al. Self-reported cognitive problems in 
testicular cancer patients: Relation to neuropsychological performance, fatigue, 
and psychological distress. Journal of Psychosomatic Research 2011; 70 : 403-
410. DOI: 10.1016/j.jpsychores.2010.12.004 
18. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth 
look at survivors' reports of impact on work, social networks, and health care 
response. Journal of Cancer Survivorship-Research and Practice 2009; 3 : 223-
232. DOI: 10.1007/s11764-009-0098-x 
19. Von Ah D, Habermann B, Carpenter JS, Schneider BL. Impact of perceived 
cognitive impairment in breast cancer survivors. European Journal of Oncology 
Nursing 2013; 17 : 236-241. 
20. Mitchell T, Turton P. ‘Chemobrain’: Concentration and memory effects in people 
receiving chemotherapy – a descriptive phenomenological study. European 
Journal of Cancer Care 2011; 20 : 539-548. DOI: 10.1111/j.1365-
2354.2011.01244.x 
21. Cheung YT, Shwe M, Tan EHJ, Chui WK, Ng R, Chan A. Acknowledging the 
relevance of cognitive changes in cancer patients: Perspectives of oncology 
practitioners in Asia. Journal of Cancer Survivorship 2013; 7 : 146-154. DOI:  
http://dx.doi.org/10.1007/s11764-012-0256-4 
22. Munir F, Kalawsky K, Lawrence C, Yarker J, Haslam C, Ahmed S. Cognitive 
intervention for breast cancer patients undergoing adjuvant chemotherapy: A 
needs analysis. Cancer Nursing 2011; 34 : 385-392. DOI: 
10.1097/NCC.0b013e31820254f3 
23. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research 
in Psychology 2006; 3: 77-101. 
24. Aitken C, Power R, Dwyer R. A very low response rate in an on‐line survey of 
medical practitioners. Australian and New Zealand Journal of Public Health 
2008; 32 : 288-289. DOI: 10.1111/j.1753-6405.2008.00232.x 
25. Brinkmann S. Qualitative Interviewing. Oxford University Press, Oxford, 2013. 
26. Curtin M, Fossey E. Appraising the trustworthiness of qualitative studies: 
Guidelines for occupational therapists. Australian Occupational Therapy Journal 
2007; 54 : 88-94. DOI: 10.1111/j.1440-1630.2007.00661.x 
27. Phillips JL, Currow DC. Cancer as a chronic disease. Collegian 2010; 17 : 47-50. 
28. Epstein R, Street RL. Patient-centered communication in cancer care: Promoting 
healing and reducing suffering. National Cancer Institute: Bethesda, MD, 2007. 
29. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient 
preferences for shared decisions: A systematic review. Patient Education and 
Counseling 2012; 86 : 9-18. DOI:10.1016/j.pec.2011.02.004  
 
 
Section II: Journal Manuscript 54 
 
30. Schagen SB, Das E, van Dam FSAM. The influence of priming and pre-existing 
knowledge of chemotherapy-associated cognitive complaints on the reporting of 
such complaints in breast cancer patients. Psycho-Oncology 2009; 18 : 674-678. 
DOI: 10.1002/pon.1454 
31. Duijts SFA, van Egmond MP, Spelten E, van Muijen P, Anema JR, van der Beek 
AJ. Physical and psychosocial problems in cancer survivors beyond return to 
work: A systematic review. Psycho-Oncology 2014; 23 : 481-492. DOI: 
10.1002/pon.3467 
32. Bradley CJ, Neumark D, Bednarek HL, Schenk M. Short-term effects of breast 
cancer on labor market attachment: Results from a longitudinal study. Journal of 
Health Economics 2005; 24 : 137-160. DOI: 10.1016/j.jhealeco.2004.07.003 
33. Player L, Mackenzie L, Willis K, Loh SY. Women's experiences of cognitive 
changes or 'chemobrain' following treatment for breast cancer: A role for 
occupational therapy? Australian Occupational Therapy Journal 2014; 61 :230-
240. DOI: 10.1111/1440-1630.12113 
34. Myers, JS. Chemotherapy-related cognitive impairment: The breast cancer 
experience. Oncology Nursing Forum 2012; 39 : 31-40. DOI: 10.1188/12.onf.e31-
e40 
35. Reid-Arndt SA, Yee A, Perry MC, Hsieh C. Cognitive and psychological factors 
associated with early posttreatment functional outcomes in breast cancer 
survivors. Journal of Psychosocial Oncology 2009; 27 : 415-434. DOI: 
10.1080/07347330903183117 
36. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer 
care: Are they effective in the UK? Lancet Oncology 2006; 7 : 935-943. DOI: 
10.1016/S1470-2045(06)70940-8 
37. Schuurs A, Green HJ. A feasibility study of group cognitive rehabilitation for 
cancer survivors: Enhancing cognitive function and quality of life. Psycho-
Oncology 2013;  22 : 1043-1049. 
38. Jiwa M, Packer TL, Merriman G, et al. Timely cancer diagnosis and management 
as a chronic condition: Opportunities for primary care. The Medical Journal of 
Australia 2008; 189 : 78-82.  
39. Newman R, Campbell C. An occupational therapy perspective in addressing 
breast cancer-related cognitive dysfunction in the survivorship phase. Physical 
Disabilities Special Interest Section Quarterly / American Occupational Therapy 
Association 2013; 36 : 1-3. 
40. Rodin G, Mackay JA, Zimmermann C, et al. Clinician-patient communication: A 
systematic review. Supportive Care in Cancer 2009; 17 : 627-644. DOI: 
10.1007/s00520-009-0601-y 
 
 
  
Section III: Appendices 55 
 
APPENDICES 
 
APPENDIX A: PSYCHO-ONCOLOGY – AUTHOR GUIDELINES FOR 
MANUSCRIPT SUBMISSION 
 
Author Guidelines 
Manuscript Submission 
All papers must be submitted via the online system. 
Psycho-Oncology operates an online submission and peer review system that allows authors 
to submit articles online and track their progress via a web interface.  
Please read the remainder of these instructions to authors and then click 
http://mc.manuscriptcentral.com/pon to navigate to the Psycho-Oncology online submission 
site, ScholarOne Manuscripts (formerly known as Manuscript Central). IMPORTANT: 
Please check whether you already have an account in the system before trying to create a new 
one. If you have reviewed or authored for the journal in the past year it is likely that you will 
have had an account created.  
File types. Preferred formats for the text and tables of your manuscript are .doc, .rtf, .ppt, 
.xls. LaTeX files may be submitted provided that an .eps or .pdf file is provided in addition 
to the source files. Figures may be provided in .tiff or .eps format.  
Please note: This journal does not accept Microsoft Word 2007 documents at this time. 
Please use Word's "Save As" option to save your document as a .doc file type. If you try to 
upload a Word 2007 document in ScholarOne Manuscripts you will be prompted to save 
.docx files as .doc files.  
Initial Submission 
Non-LaTeX Users: Upload your manuscript files. At this stage, further source files do not 
need to be uploaded. 
LaTeX Users: For reviewing purposes you should upload a single .pdf that you have 
generated from your source files. You must use the File Designation "Main Document" from 
the dropdown box.  
Revision Submission 
Non-LaTeX Users: Editable source files must be uploaded at this stage. Tables must be on 
separate pages after the reference list, and not be incorporated into the main text. Figures 
should be uploaded as separate figure files. 
LaTeX Users: When submitting your revision you must still upload a single .pdf that you 
have generated from your now revised source files. You must use the File Designation "Main 
Document" from the dropdown box. In addition you must upload your TeX source files. For 
all your source files you must use the File Designation "Supplemental Material not for 
Section III: Appendices 56 
 
review". Previous versions of uploaded documents must be deleted. If your manuscript is 
accepted for publication we will use the files you upload to typeset your article within a 
totally digital workflow. 
Copyright and Permissions 
If your paper is accepted, the author identified as the formal corresponding author for the 
paper will receive an email prompting them to login into Author Services; where via the 
Wiley Author Licensing Service (WALS) they will be able to complete the license agreement 
on behalf of all authors on the paper.  
For authors signing the copyright transfer agreement 
If the OnlineOpen option is not selected the corresponding author will be presented with the 
copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be 
previewed in the samples associated with the Copyright FAQs below:  
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp.  
For authors choosing OnlineOpen 
If the OnlineOpen option is selected the corresponding author will have a choice of the 
following Creative Commons License Open Access Agreements (OAA):  
 Creative Commons Attribution License OAA 
 Creative Commons Attribution Non-Commercial License OAA  
 Creative Commons Attribution Non-Commercial -NoDerivs OAA  
To preview the terms and conditions of these open access agreements please visit the 
Copyright FAQs hosted on Wiley Author Services and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html. 
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and 
members of the Research Councils UK (RCUK) you will be given the opportunity to publish 
your article under a CC-BY license supporting you in complying with Wellcome Trust and 
Research Councils UK requirements. For more information on this policy and the Journal’s 
compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement. 
Submission of a manuscript will be held to imply that it contains original unpublished work 
and is not being submitted for publication elsewhere at the same time. Submitted material 
will not be returned to the author, unless specifically requested.  
Manuscript style. The language of the journal is English. 12-point type in one of the 
standard fonts: Times, Helvetica, or Courier is preferred. It is not necessary to double-line 
space your manuscript. There should be a separate title page with full information and 
another page for an abstract, prior to the Introduction. Tables must be on separate pages after 
the reference list, and not be incorporated into the main text. Figures should be uploaded as 
separate figure files.  
Section III: Appendices 57 
 
 During the submission process you must enter the full title, short title of up to 70 
characters and names and affiliations of all authors. Give the full address, including 
email, telephone and fax, of the author who is to check the proofs.  
 Include the name(s) of any sponsor(s) of the research contained in the paper, along with 
grant number(s).  
 Enter an abstract of up to 250 words for all articles. An abstract is a concise summary of 
the whole paper, not just the conclusions, and is understandable without reference to the 
rest of the paper. It should contain no citation to other published work. You must submit 
your abstract according to these headings: objective; methods; results; conclusions.  
 Include up to six keywords which must contain the words cancer and oncology that 
describe your paper for indexing purposes.  
 Research Articles should not exceed 4000 words (including no more than four figures 
and/or tables) plus up to 40 references. Review papers of up to 6000 words will be 
considered, with 80 references - authors should contact the Editors for advice. All papers 
should use the following headings: Background, Methods (including statistical methods), 
Results, Conclusions. Word counts should include the title page, abstract, main 
manuscript, tables and figures, but exclude the references.  
 Qualitative manuscript submissions should usually be based on a minimum of 20 
respondents. Authors may contact the Editors if they require further details.  
 When submitting a randomised trial, please complete and supply the CONSORT 
checklist and include diagram. For systematic reviews or meta-analyses please complete 
the PRISMA checklist and include flowchart. Please complete and supply AMSTAR for 
systematic reviews which are narrative reviews not meta-analyses.  
 When you upload your files on the ScholarOne Manuscripts site, please use the file 
designation 'Supplementary File for Review' for any files which need to be seen by 
reviewers but should not be included in the final published version of your paper (if 
accepted for publication). This may include CONSORT checklists, PRISMA flowcharts, 
or tables and figures which are referred to in the text but which can appear online only as 
Supporting Information.  
Psycho-Oncology publishes Clinical Correspondence. This replaces the previous Brief 
Reports section. Items submitted as Clinical Correspondence may include:  
1. Feasibility studies 
2. Case studies 
3. Phase I/II clinical trials 
4. Questionnaire development studies 
5. Service Development 
6. Commentary 
7. Novel clinical techniques 
The following requirements apply to this section: 
1. Five succinct key points (and no abstract) 
Section III: Appendices 58 
 
2. Text 1500 words maximum, including the title page, abstract, figures and tables, but 
excluding the references.  
3. Two figures/tables maximum 
4. Ten references maximum 
 Letters to the Editor should not exceed 400 words including a maximum of one 
reference. No figures or tables. Please note that if Letters to the Editor include a 
comment on a previously published paper the authors of said paper should be allowed 4 
weeks in which to respond. If no response after 4 weeks the Letter will simply be 
accepted with an Editor's Footnote "The authors of [Title of Paper previously published] 
offered no comments".  
All abbreviations except for SI symbols should be written in full the first time they appear. 
Generic or clinical names should be used for all compounds: materials and products should 
be identified. The species of any animals used should be stated precisely. Sources of unusual 
materials and chemicals, and the manufacturer and model of equipment should be indicated. 
materials and products should be identified in the text followed by the trade name in brackets.  
Reference style. References should be cited in the text by number within square brackets and 
listed at the end of the paper in the order in which they appear in the text. All references must 
be complete and accurate. If necessary, cite unpublished or personal work in the text but do 
not include it in the reference list. Where possible the DOI for the reference should be 
included at the end of the reference. Online citations should include date of access. 
References should be listed in the following style:  
Decker, CL. Social support and adolescent cancer survivors: A review of the 
literature. Psycho-Oncology 2007; 16 : 1-11.  
Peterson AC, Leffert N. What is special about adolescence? In Psychosocial 
Disturbances in Young People: Challenges for Prevention, Rutter M (ed.).Cambridge 
University Press: Cambridge, 1997;3-36.  
Illustrations. Upload each figure as a separate file in either .tiff or .eps format, with the 
figure number and the top of the figure indicated. Compound figures e.g. 1a, b, c should be 
uploaded as one figure. Tints are not acceptable. Lettering must be of a reasonable size that 
would still be clearly legible upon reduction, and consistent within each figure and set of 
figures. Where a key to symbols is required, please include this in the artwork itself, not in 
the figure legend. All illustrations must be supplied at the correct resolution:  
Black and white and colour photos - 300 dpi 
Graphs, drawings, etc - 800 dpi preferred; 600 dpi minimum 
Combinations of photos and drawings (black and white and colour) - 500 dpi  
Tables should be part of the the main document and should be placed after the references. If 
the table is created in excel the file should be uploaded separately.  
Section III: Appendices 59 
 
Colour Policy. Where colour is necessary to the understanding of the figures, colour 
illustrations will be reproduced in the journal without charge to the author, at the Editor's 
discretion.  
Ethics. Authors of research papers should provide information about funding, a Conflict of 
Interest statement, details of ethical committee review, and (if the paper is a clinical trial) 
details of trial registration. All of these declarations should be in the research paper itself, not 
a covering letter. If authors include named individuals in the Acknowledgements they must 
confirm that they have approval from those individuals in their covering letter  
Post Acceptance 
Further Information. For accepted manuscripts the publisher will supply proofs to the 
submitting author prior to publication. This stage is to be used only to correct errors that may 
have been introduced during the production process. Prompt return of the corrected proofs, 
preferably within two days of receipt, will minimise the risk of the paper being held over to a 
later issue. Free access to the final PDF offprint of your article will be available via Author 
Services only. Please therefore sign up for Author Services if you would like to access your 
article PDF offprint and enjoy the many benefits the service offers.  
Authors Resources: Manuscript now accepted for publication?  
If so, check out our suite of tools and services for authors and sign up for:  
Article Tracking 
E-mail Publication Alerts 
Personalization Tools 
Cite EarlyView Articles 
To link to an article from the author’s homepage, take the DOI (digital object identifier) and 
append it to "http://dx.doi.org/" as per following example: 
DOI 10.1002/hep.20941, becomes http://dx.doi.org/10.1002/hep.20941.  
To include the DOI in a citation to an article, simply append it to the reference as in the 
following example: 
Oestreicher, N., The cost of adjuvant chemotherapy in patients with early-stage breast 
carcinoma, Cancer 10(1) , pp. 2054 - 2062, DOI: 10.1002/cncr.21464.  
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to 
publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in 
the same way as any other article. They go through the journal's standard peer-review process 
and will be accepted or rejected based on their own merit.  
 
 
 
Section III: Appendices 60 
 
APPENDIX B: INTERVIEW SCHEDULE 
 
Interview Schedule 
Question 1: 
Please describe your perception of cognitive changes in your patients from diagnosis right 
through to the survivorship phase? 
Follow up questions if required: 
 Do you talk with your patients about cognitive changes? 
o If yes, what are the kinds of cognitive changes that patients describe to you? 
o If no, have you heard about possible cognitive changes in cancer patients? 
 What is the general pattern and time frame of any cognitive changes in your patients 
throughout the cancer trajectory?  
Question 2 (if not already answered in question 1): 
What do you believe are the underlying causes of these changes? 
 Do you think anti-cancer treatments such as chemotherapy, radiotherapy and hormonal 
therapy contribute to cognitive changes?   
 If yes, how much do you think each treatment modality is responsible?  
Question 3:  
Are there specific characteristics that you can identify about the people who report cognitive 
changes? 
 
Follow up questions if required: 
 
 How do you perceive differences in cognitive changes amongst patients of different 
tumour groups? 
 Are there some patients who consistently report cognitive changes more than others? 
 
Question 4: 
How do you approach the possibility of cognitive changes with your patients? 
Follow up questions if required: 
 Do you routinely ask your patients whether they are experiencing cognitive changes?  
 At what stage would you ask your patient whether they are experiencing cognitive 
changes? 
 If your patient reports changes in cognition, what action do you take?  
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Question 5:   
To improve future practice and maximise quality of life for patients, what do you believe are 
some ways to address cognitive changes with patients from cancer diagnosis right through to 
the survivorship phase? 
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